Formulation and biopharmaceutical evaluation of a transdermal patch containing letrozole
1Department of Pharmaceutical Sciences, Shenyang Pharmaceutical University, China.
Biopharmaceutics & Drug Disposition
|February 9, 2010
Summary
This study developed a novel drug-in-adhesive (DIA) transdermal patch for letrozole, an effective breast cancer treatment. The transdermal patch offers a patient-friendly alternative to oral letrozole, demonstrating comparable pharmacokinetic profiles.
Area of Science:
- Pharmaceutical Sciences
- Oncology
- Drug Delivery Systems
Background:
- Breast cancer treatment often involves aromatase inhibitors like letrozole.
- Oral administration of letrozole can have limitations.
- Transdermal drug delivery systems offer potential for improved therapeutic outcomes.
Purpose of the Study:
- To formulate a novel drug-in-adhesive (DIA) transdermal patch containing letrozole.
- To evaluate the percutaneous penetration and pharmacokinetics of transdermal letrozole compared to oral administration.
- To investigate formulation factors influencing letrozole permeation through the skin.
Main Methods:
- Formulation of DIA transdermal patches with various pressure-sensitive adhesives (PSAs) and enhancers.
- In vitro evaluation of letrozole permeation through skin.
- In vivo pharmacokinetic studies in rats comparing transdermal patches with oral letrozole solution.
- Analysis of pharmacokinetic parameters including mean residence time (MRT).
Main Results:
- A specific formulation using DURO-TAK 87-4098, Azone, and propylene glycol exhibited the highest letrozole permeation.
- Transdermal administration of letrozole via the optimized DIA patch resulted in significantly different MRT compared to oral administration in rats.
- In vitro penetration data accurately predicted in vivo plasma concentrations.
Conclusions:
- Letrozole-loaded transdermal patches represent a viable, patient-friendly therapeutic system for breast cancer treatment.
- The DIA transdermal patch offers sustained dosing and potentially high local drug concentrations.
- This transdermal strategy provides a useful alternative for breast cancer prevention and management.
Related Concept Videos
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:28Biopharmaceutics and Pharmacokinetics: Overview
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.